IFNA1 and antiphospholipid syndrome: We have also implemented the screening for anti-phospholipid syndrome (APS), a pro-thrombotic autoimmune syndrome that is highly linked to IFN release, and that therefore may be exacerbated by interferon-based therapies [20, 21].